Meningococcal Vaccines Market Size, Share, Growth Analysis, By Vaccine Type (Polysaccharide Vaccines, Conjugate Vaccines), By Brand (Menactra, Menveo), By Age Group (Infants, Children), By End User (Hospitals, Clinics), By Region - Industry Forecast 2025-2032

Meningococcal Vaccines Market size was valued at USD 3.5 Billion in 2023 and is poised to grow from USD 3.71 Billion in 2024 to USD 5.96 Billion by 2032, growing at a CAGR of 6.1% during the forecast period (2025-2032).

The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), there are an estimated 1.2 million cases of bacterial meningitis worldwide. Furthermore, increasing immunization programs, growing awareness about the disease, and increasing R&D activities related to meningococcal vaccines will drive the meningococcal vaccines market growth during the forecast period. 

Campaigns and awareness programs are run by government & non-government organizations, such as the National Meningitis Association (NMA), the Meningitis Research Foundation of Canada, the Meningitis B Action Project, and others. These organizations help to promote ongoing research and new prevention strategies. Thus, these factors are expected to fuel the growth of the meningococcal vaccines industry in the coming years. 

The meningococcal vaccine is designed to protect against Neisseria meningitidis infection. Vaccines targeting several strains of meningococcus including A, B, C, W-135 and Y are available. Vaccines can be monovalent, targeting a specific meningococcus, or multivalent in nature. The major factors driving the rise of the global meningococcal vaccines market are increasing availability and popularity of travel vaccine, advancement in R&D related to vaccine technology. Their increased inclusion in national immunization programs is expected to contribute to the growth of the market. Stringent regulatory guidelines are expected to hamper market growth.